At time of ASCT, patients with IP had significantly increased percentages of CD3<sup>+</sup>CD8<sup>+</sup>CD57<sup>+</sup> CD28<sup>-</sup> (<i>P</i> = 0.05) and CD3<sup>+</sup>CD4<sup>+</sup>LAG3<sup>+</sup> (<i>P</i> = 0.0022) T-cells, as well as less CD56<sup>bright</sup> and CD56<sup>dim</sup> NK cells bearing activated markers such as CD69, NKG2D, and CD226. This evidence concerns the gene NCAM1 and incontinentia pigmenti.